Drug delivery systems for the topical treatment of cutaneous leishmaniasis

Expert Opinion on Drug Delivery

Volumn 9, Issue 9, 2012, Pages 1083-1097

  Carneiro, Guilherme ^a   Aguiar, Marta Gontijo ^b   Fernandes, Ana Paula ^a   Ferreira, Lucas Antônio Miranda ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CENTRO UNIVERSITÁRIO NEWTON PAIVA   (Brazil)

Author keywords

Amphotericin B; Cutaneous leishmaniasis; Lipid nanocarriers; Liposomes; Paromomycin; Skin penetration; Topical treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; BUPARVAQUONE; HYDROXYETHYLCELLULOSE; IMIQUIMOD; LIPOSOME; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PAROMOMYCIN; SOLID LIPID NANOPARTICLE;

CREAM; DIARRHEA; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; HUMAN; HYDROGEL; NAUSEA; NEPHROTOXICITY; NONHUMAN; OINTMENT; OTOTOXICITY; REVIEW; SKIN LEISHMANIASIS; SKIN PERMEABILITY; SKIN STRUCTURE; VOMITING;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LEISHMANIASIS, CUTANEOUS; NAPHTHOQUINONES; PAROMOMYCIN; PHOSPHORYLCHOLINE; SKIN ABSORPTION;

EID: 84865314346     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.701204     Document Type: Review

References (100)

1. Sacks DL. Metacyclogenesis in Leishmania promastigotes. Exp Parasitol 1989;69:100-3 (Pubitemid 19187905)
2. Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 2011;9:604-15
3. Schriefer A, Wilson ME, Carvalho EM. Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis 2008;21:483-8
4. Grimaldi G Jr, Tesh RB, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg 1989;41:687-725 (Pubitemid 20022744)
5. Berman J. Visceral leishmaniasis in the New World & Africa. Indian J Med Res 2006;123:289-94 (Pubitemid 43905570)
6. Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002;3:538-44
7. Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 2005;14:1337-46 (Pubitemid 41601450)
8. Soto JM, Toledo JT, Gutierrez P, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002;66:147-51 (Pubitemid 34755645)
9. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 2003;16:397-401 (Pubitemid 37267258)
10. Armijos RX, Weigel MM, Calpovina M, et al. Comparison of the effectiveness of two topical paromomycin treatment versus meglumine antimoniate for new world cutaneous leishmaniasis. Acta Trop 2004;91:153-60 (Pubitemid 38952716)
11. Santos AM, Noronha EF, Ferreira LA, et al. Efeito de uma formulacao hidrofilica de paromomicina topica na leishmaniose cutanea em pacientes com contra-indicacoes de tratamento com antimonial pentavalente. Rev Soc Bras Med Trop 2008;41:444-8
12. Ben-Salah A, Buffet PA, Morizot G, et al. WR279, 396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double Blind, placebo controlled study. Plos Negl Trop Dis 2009;3:432
13. Neal RA, Murphy AG, Olliaro P, Croft SL. Aminosidine ointments for the treatment of experimental cutaneous. Trans R Soc Trop Med Hyg 1994;88:223-35
14. Asilian A, Jalayer T, Whitworth JAG, et al. A randomized placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995;53:648-51 (Pubitemid 26036354)
15. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14 (Pubitemid 32737532)
16. Papakostas D, Rancan F, Sterry W, et al. Nanoparticles in dermatology. Arch Dermatol Res 2011;303:533-50
17. Pierre MBR, Costa ISM. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch Dermatol Res 2011;303:607-21
18. El Maghraby GM, Barry BW, William SD. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci 2008;34:203-22
19. Carneiro G, Santos DCM, Oliveira MC, et al. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res 2010;20:16-23
20. Chiang B, Essick E, Ehringer W, et al. Enhancing skin wound healing by direct delivery of intracellular adenosine triphosphate. Am J Surg 2007;193:213-18 (Pubitemid 46107917)
21. Lee JP, Jalili RB, Tredget EE, et al. Antifibrogenic effects of liposome-encapsulated IFN-2b cream on skin wounds in a fibrotic rabbit ear model. J Interf Cytok Res 2005;25:627-31 (Pubitemid 41507818)
22. Langer S, Botteck NM, Bosse B, et al. Effect of polyvinylpyrrolidone- iodine liposomal hydrogel on wound microcirculation in SKH1-hr hairless mice. Eur Surg Res 2006;38:27-34
23. Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs 2008;17:787-94 (Pubitemid 351843621)
24. Fernandez MM, Malchiode EL, Algranati ID. Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells. Antimicrob Agents Chemother 2011;55:86-93
25. Kanyok TP, Killian AD, Rodvold KA, Danziger LH. Pharmacokinetics of intramusculary administered aminosidine in healthy subjects. Antimicrob Agents Chemother 1997;41:982-6 (Pubitemid 27194172)
26. Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356:2571-81 (Pubitemid 46961002)
27. Aguiar MG, Silva D, Nunan FA, et al. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. J Antimicrob Chemother 2009;64:1234-40
28. Paris C, Louseau P, Bories C, Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004;48:852-9 (Pubitemid 38280335)
29. Croft SL, Engel J. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc of Trop Med Hyg 2006;100(Suppl 1):1-4
30. Rakotomanga M, Blanc S, Gaudin K, et al. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007;51:1425-30 (Pubitemid 46586825)
31. Wadhone P, Maiti M, Agarwal R, et al. Miltefosine promotes IFN-gamma-dominated antileishmanial immune response. J Immunol 2009;182:7146-54
32. Soto J, Toledo J, Gutierrez P, et al. Treatment of american cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001;33:E57-61
33. Kaminsky R. Miltefosine zentaris. Current Opin Investig Drugs 2002;3:550-4
34. Berman J. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug and Metab Toxicol 2008;4:1209-12
35. Golenser J, Frakenburg S, Ehrenfreund T, Domb AJ. Efficacious treatment of experimental leishmaniasis with amphotericin B-Arabinogalactan water-soluble derivatives. Antimicrob Agents Chemother 1999;43:2209-14 (Pubitemid 29421202)
36. Baginski M, Czub J. Amphotericin B and. Its New Derivatives-Mode of Action. Curr Drug Metab 2009;10:459-69
37. Croft S, Olliaro P. Leishmaniasis chemotherapy: challenges and opportunities. Clin Microbiol Infect 2011;17:1478-83
38. Cohen BE. Amphotericin B toxicity and lethality: a tale of two channels. Int J Pharm 1998;162:95-106 (Pubitemid 28166095)
39. Vyas SP, Gupta S. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomedicine 2006;1:417-32
40. Erbagci Z, Tuncel AA, Erkilic S, Zer Y. Successful treatment of antifungal-and cryotherapy-resistant subcutaneous hyalohyphomycosis in an immunocompetent case with topical 5% imiquimod cream. Mycopathologia 2005;159:521-6 (Pubitemid 40876669)
41. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous Leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001;33:1847-51 (Pubitemid 33105123)
42. El-On J, Bazarsky E, Sneir R Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator imiquimod. Exp Parasitol 2007;116:156-62 (Pubitemid 46602257)
43. Slade HB, Owens ML, Tomai MA, Miller RJ. Imiquimod 5% cream (Aldara™). Exp Opin Invest Drugs 1998;7:437-49
44. Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003;149:5-8 (Pubitemid 38064505)
45. Ganier T, Mantyla A, Jarvinen T, et al. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother 2007;60:802-10 (Pubitemid 47434259)
46. Seifert K. Structures, targets and recent approaches in antileishmanial drug discovery and development. Open Med Chem J 2011;5:31-9
47. Moser K, Kriwet K, Naik A, et al. Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm 2001;52:103-12 • An excellent review on the mechanisms and alternatives for skin penetration enhancement. (Pubitemid 32755887)
48. Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol 2008;17:1063-72
49. Fang JY, Leu YL. Prodrug strategy for enhancing drug delivery via skin. Curr Drug Discov Technol 2006;3:211-24
50. Trommer H, Neubert RH. Overcoming the stratum corneum: the modulation of skin penetration. A review. Skin Pharmacol Physiol 2006;19:106-21 (Pubitemid 43725821)
51. Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96 (Pubitemid 47277438)
52. Neuber H. Leishmaniasis. J Dtsch Dermatol Ges 2008;6:754-652
53. Gattu S, Maibach HI. Enhanced absorption through damaged skin: an overview of the in vitro human model. skin. Pharmacol Physiol 2010;23:171-6
54. Markle WH, Makhoul K. Cutaneous Leishmaniasis: recognition and Treatment. Am Fam Physican 2004;69:1455-60 (Pubitemid 38380766)
55. El-On J, Jacobs GP, Witztum E, Greenblatt CL. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob Agents Chemother 1984;26:745-51 (Pubitemid 15211674)
56. El-On J, Jacobs GP, Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 1988;4:76-81
57. Carter KC, Alexander J, Baille AJ. Studies on the topical treatment of experimental cutaneous leishmaniasis: the therapeutic effect of methyl benzethonium chloride and the aminoglycosides, gentamicin and paromomycin. Ann Trop Med Parasitol 1989;88:233-9 (Pubitemid 19183515)
58. Grogl M, Schuster BG, Ellis WY, Berman JD. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin. J Parasitol 1999;85:354-9 (Pubitemid 29251857)
59. El-On J, Livshin R, Even-Paz Z, et al. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986;87:1110-86
60. Soto J, Hernandez N, Mejia H, et al. Successful treatment of new world cutaneous leishmaniasis with a combination of topical paromomycin/ methylbenzethonium chloride and injectable meglumine antimoniate. Clin Infect Dis 1995;20:47-51
61. Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/ methylbenzetonium chloride plus parenteral meglumine antimoniate as treatment for american cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998;26:56-8 (Pubitemid 28068155)
62. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hig 2001;65:466-70 (Pubitemid 33134578)
63. Bryceson ADM, Murphy A, Moody AH. Treatment of "Old World" cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Trans R Soc Trop Med Hyg 1994;88:226-8 (Pubitemid 24139698)
64. Ben-Salah A, Zakraoui H, Zaatour A, et al. A randomized placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995;53:162-6
65. Asilian A, Jalayer T, Nilforoohzadeh M, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003;81:353-9 (Pubitemid 36644261)
66. Castro GA, Nascimento DS, Nunan EA, et al. In vitro skin permeation of paromomycin from topical formulations across normal and stripped hairless mouse skin. S. T. P. Pharm Sci 2003;13:203-8 (Pubitemid 36903550)
67. Simon GA, Maibach HI. The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations-an overview. Skin Pharmacol Appl skin Physiol 2000;13:229-34 (Pubitemid 30666020)
68. Jacobi U, Kaiser M, Toll R, et al. Porcine ear skin: an in vitro model for human skin. Skin Res Technol 2007;13:19-24 (Pubitemid 46152448)
69. Walker M, Hulme TA, Rippon MG, et al. In Vitro models for the percutaneous delivery of active tissue repair agents. J Pharm Sci 1997;86:1379-84 (Pubitemid 28018318)
70. Grevelink AS, Lerner EA. Leishmaniasis. J Am Acad Dermatol 1996;34:257-72 (Pubitemid 26063997)
71. Lalor CB, Flynn GL, Weiner N. Formulation factors affecting release of drug from topical formulations. II. Effect of solubility on in vitro delivery of a series of n-alkyl p-aminobenzoates. J Pharm Sci 1995;84:673-6
72. Goncalves GS, Fernandes AP, Souza RCC, et al. Activity of a paromomycin hydrophilic formulation for tropical treatment of infections by Leishmania (Leshmania) amazonensis and Leishmania (Vianna) braziliensis. Acta Trop 2005;93:161-7 (Pubitemid 40126250)
73. Mussi SV, Fernandes AP, Ferreira LA. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Parasitol Res 2007;100:1221-6 (Pubitemid 46450539)
74. Aguiar MG, Pereira AM, Fernandes AP, Ferreira LA. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis. Antimicrob Agents Chemother 2010;54:4699-704
75. Coderch L, Fonollosa J, De Pera M, et al. Influence of cholesterol on liposome fluidity by EPR Relationship with percutaneous absorption. J Control Release 2000;68:85-95 (Pubitemid 30407064)
76. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev 2002;54(Suppl 1):S41-55 (Pubitemid 35379954)
77. Kim MK, Chung SJ, Lee MH, et al. Targeted and sustained delivery of hydrocortisone to normal stratum corneum-removed skin without enhanced skin absorption using a liposome gel. J Control Release 1997;46:243-51
78. Mohebali M, Fotouhi A, Hoosmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007;103:33-40 (Pubitemid 47078934)
79. Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008;78:210-11 (Pubitemid 351844550)
80. Schmidt-Ott R, Klenner T, Overath P, Aebischer T. Topical treatment with hexadecylphosphocholine (Miltex®) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999;93:85-90 (Pubitemid 29123731)
81. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators Imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999;179:1485-94 (Pubitemid 29246599)
82. Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007;44:1549-54 (Pubitemid 46871500)
83. Al-Mutairi N, Alshiltawy M, El Khalawany M, et al. Treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination. Int J Dermatol 2009;48:862-9
84. Miranda-Verastegui C, Tulliano G, Gyorkos TW, et al. First-Line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis 2009;3:e491
85. Meymandi SS, Javadi A, Dabiri S, et al. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy. Arch Iran Med 2011;14:238-43
86. Seeberger J, Daoud S, Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol 2003;42:576-9 (Pubitemid 36869158)
87. Mantyla A, Garnier T, Rautio J, et al. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J Med Chem 2004;47:188-95 (Pubitemid 38040502)
88. Garnier T, Mantyla A, Jarvinen T, et al. Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis. J Pharm Pharmacol 2007;59:41-9 (Pubitemid 46133042)
89. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007;4:297-305 (Pubitemid 47554274)
90. Wu X, Landfester K, Musyanovych A, Guy RH. Disposition of charged nanoparticles after their topical application to the skin. Skin Pharmacol Physiol 2010;23:117-23
91. Solans C, Izquierdo P, Nolla J, et al. Nano-emulsions. Curr Opin Coll Int Science 2005;10:102-10 (Pubitemid 41565542)
92. Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm 2004;30:289-96 (Pubitemid 38451753)
93. Jaafari MR, Bavarsad N, Bazzaz BSF, et al. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2009;53:2259-65
94. Egito EST, Araujo IB, Damasceno BPGL, Price JC. Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity. J Pharm Sci 2002;91: 2354-66 (Pubitemid 35231198)
95. Frankeburg S, Glick D, Klaus S, Barenholz Y. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B. Antimicrob Agents Chemother 1998;42:3092-6 (Pubitemid 28553723)
96. Vardy D, Barenholz Y, Naftoliev N, et al. Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B. Trans R Soc Trop Med Hyg 2001;95:184-6 (Pubitemid 34947384)
97. Zvulunov A, Cagnano E, Frankenburg S, et al. Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin. B. Pediatr Infect Dis J 2003;22:567-9 (Pubitemid 36782201)
98. Santos CM, Oliveira RB, Arantes VT, et al. Amphotericin B-loaded Nanocarriers for Topical Treatment of Cutaneous Leishmaniasis: Development, Characterization, and In Vitro Skin Permeation Studies. J Biomed Nanotechnol 2012;8:322-9. Copyright © American Scientific Publishers. • This paper describes the preparation and characterization of AmB-loaded nanocarries. It also investigates the topical delivery of AMB from the nanosystems by conducting permeation studies.
99. The United Pharmacopeia; the national formulary-USP 31. United States Pharmacopeial convention, Rockville; 2008
100. British Pharmacopeia. Her Majesty's Stationary Office, London; 2005